Chemspace Enables Fast Delivery of Compounds From The Freedom Space

October 21, 2024 09:00 PM AEDT | By EIN Presswire
 Chemspace Enables Fast Delivery of Compounds From The Freedom Space
Image source: EIN Presswire

KYIV, UKRAINE, October 21, 2024 /EINPresswire.com/ -- Chemspace, an expert in the generation and exploration of ultra-large chemical datasets, and Enamine, a global leader in supplying small molecules and early drug discovery services, are pleased to announce an expansion of their collaboration to improve delivery times of molecules from Chemspace Freedom Space.

Chemspace Freedom Space is a unique chemical library of five billion make-on-demand molecules. It was created utilizing a combination of machine learning (ML) and experimental knowledge applied to the collection of in-stock building blocks from several suppliers. This innovative approach yielded a diverse and high-quality compound library for researchers that is also a valued addition to Enamine REAL Space.

Enamine will leverage extensive synthesis capabilities and production facilities in Europe, namely at Enamine Germany – its Frankfurt am Main Site, allowing Chemspace to enable the rapid synthesis and delivery of the Freedom compounds within 4-5 weeks. Such joint effort also further supports the mission of both companies to provide global research initiatives with the best possible tools and resources.

"We understand the importance of fast delivery of compounds upon performing the DMTA cycle," said Olga Tarkhanova, Ph.D., the CEO of Chemspace. "Our customers rely on us to get the Freedom compounds as quickly as possible to advance their investigation projects. That is why we are taking proactive steps to enhance our service and meet our high standards."

Vladimir Ivanov, Ph.D., Executive Vice President at Enamine, added, "Establishing Enamine’s Germany Site gives us access to state-of-the-art synthesis technologies, like total synthesis, synthesis of macrocycles and peptides, and local production capacity. The latter means that we now can offer faster production of compound libraries thus speeding up the drug discovery and helping bring innovative ideas to market faster."

"By combining our synthetic expertise with Chemspace's ability to provide order management and logistics, we are providing a seamless solution for researchers, ensuring they get the compounds from the Freedom Space they need faster than ever before," continued Ivan Kondratov, Ph.D., Head of Medicinal Chemistry at Enamine Germany.

𝐀𝐛𝐨𝐮𝐭 𝐂𝐡𝐞𝐦𝐬𝐩𝐚𝐜𝐞. Chemspace provides a state-of-the-art platform for drug discovery solutions, offering access to over 2.7 Trillion molecules from in-stock and make-on-demand (Enamine xREAL and MADE collections and Chemspace Freedom Space). Chemspace supports researchers in hit discovery, optimization, and expanding molecular exploration utilizing Computational Chemistry, Bioinformatics, and Machine Learning. With end-to-end services spanning the Drug Discovery process up to pre-clinical studies, Chemspace helps identify, source, deliver, and test molecules. For more information, visit https://chem-space.com

𝐀𝐛𝐨𝐮𝐭 𝐄𝐧𝐚𝐦𝐢𝐧𝐞. Enamine is a scientifically driven integrated discovery Contract Research Organization with unique partnering opportunities for exploring new chemical space. The company combines access to the in-house produced screening compounds (4.4M in stock) and building blocks (300K in-stock) with a comprehensive platform of integrated discovery services to advance and accelerate the efforts in Drug Discovery. For more details, visit https://enamine.net. In 2023 Enamine has established a new site in Germany, located in Höchst Industrial Park (Frankfurt am Main) - Enamine Germany, which expands Enamine's reach in Europe and provide local access to its renowned services. For more details visit https://enamine.de.

Vladimir Ivanov
Enamine Ltd.
email us here
Visit us on social media:
Facebook
X
LinkedIn
Instagram

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.